AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Compass Therapeutics Inc. (NASDAQ:CMPX)
2.02 USD
-0.030 1.463%Sponsored Reports
Loading...
| Previous Close (in USD) | 2.05 |
|---|---|
| Change | -0.030 1.463% |
| 52 W H/L (in USD) | 6.880/1.665 |
| EBITDA (in USD) | -72.563M |
| PE Ratio | -- |
| Volume | 9276475 |
| Diluted Eps TTM | -0.42 |
| Total Assets (in USD) | 219.588M |
|---|---|
| Total Liabilities (in USD) | 22.797M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 30.643M |
| Market Cap (in USD) | 943.661 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | -- |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Compass Therapeutics Inc.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Employees: 39
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Thomas J. Schuetz M.D., Ph.D. | Co-Founder, CEO & Director | 1961 |
| 2. | Dr. Vered Bisker-Leib MBA, Ph.D. | Pres & COO | 1971 |
| 3. | Mr. Neil L. Lerner CPA | VP of Fin. | 1967 |
| 4. | Mr. Jonathan Anderman J.D. | VP, Head of Legal & Corp. Sec. | NA |
| 5. | Anna Gifford | Communications Mang. | NA |
| 6. | Dr. Peter F. Moesta Ph.D. | Interim Head of CMC | NA |
| 7. | Dr. Vered Bisker-Leib M.D., MBA, Ph.D. | Chief Executive Officer | 1972 |
| 8. | Dr. Thomas J. Schuetz M.D., Ph.D. | Co-Founder, President of Research & Development and Vice Chair | 1961 |
| 9. | Mr. Neil L. Lerner CPA | Vice President of Finance | 1967 |
| 10. | Mr. Jonathan Anderman J.D. | VP, Head of Legal & Corporate Secretary | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.330 0.758% | 43.45 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
0.000 0.000% | 43 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-7.360 1.604% | 462.17 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+2.010 0.331% | 612.07 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Income Before Tax | -66.489M | -49.375M | -42.494M | -39.225M | -82.181M |
| Minority Interest | - | - | - | - | - |
| Net Income | -66.489M | -49.375M | -42.494M | -36.795M | -82.551M |
| Selling General Administrative | 16.87M | 15.133M | 12.243M | 11.658M | 10.927M |
| Gross Profit | - | 0.85M | -1.89M | - | - |
| Reconciled Depreciation | 1.472M | 1.753M | 1.89M | 1.904M | 1.624M |
| Ebit | - | -56.625M | -50.363M | -41.655M | -81.882M |
| Ebitda | -72.839M | -54.872M | -48.473M | -37.391M | -29.611M |
| Depreciation And Amortization | - | 1.753M | 1.89M | 4.264M | 52.271M |
| Operating Income | -72.839M | -56.625M | -50.363M | -41.655M | -81.882M |
| Other Operating Expenses | - | 57.475M | 50.363M | 41.655M | 31.264M |
| Interest Expense | - | - | - | 2.36M | 0.37M |
| Tax Provision | - | 0M | 0M | 0M | 0M |
| Interest Income | 6.4M | 7.3M | 7.869M | 2.36M | 0.029M |
| Net Interest Income | 6.4M | 7.3M | 7.869M | 2.36M | -0.341M |
| Income Tax Expense | - | - | - | -2.43M | 0.37M |
| Total Revenue | 0M | 0.85M | 0M | 0M | 0M |
| Total Operating Expenses | 72.839M | 57.475M | 50.363M | 41.655M | 31.264M |
| Cost Of Revenue | - | - | 1.89M | - | - |
| Total Other Income Expense Net | 6.35M | 7.25M | 7.869M | 2.43M | -0.299M |
| Net Income From Continuing Ops | -66.489M | -49.375M | -42.494M | -39.225M | -82.181M |
| Net Income Applicable To Common Shares | - | - | - | -39.225M | -82.181M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Total Assets | 219.588M | 140.403M | 156.875M | 199.645M | 153.757M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 0.913M | 6.029M | 1.42M | 8.182M | 2.591M |
| Total Liab | 22.797M | 15.171M | 8.337M | 18.007M | 13.679M |
| Total Stockholder Equity | 196.791M | 125.232M | 148.538M | 181.638M | 140.078M |
| Other Current Liab | 11.383M | 6.287M | 2.514M | 11.69M | 8.775M |
| Common Stock | 0.018M | 0.013M | 0.013M | 0.013M | 0.01M |
| Capital Stock | 0.018M | 0.013M | 0.013M | 0.013M | 0.01M |
| Retained Earnings | -431.172M | -364.683M | -315.308M | -272.814M | -233.589M |
| Good Will | - | - | - | - | - |
| Other Assets | - | - | - | 0.32M | 0.32M |
| Cash | 30.643M | 43.483M | 24.228M | 34.946M | 144.514M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 13.968M | 8.874M | 7.801M | 16.169M | 10.631M |
| Current Deferred Revenue | - | - | - | - | - |
| Net Debt | -20.814M | -36.849M | -22.495M | -32.011M | -140.477M |
| Short Term Debt | 1M | 0.338M | 1.197M | 1.097M | 0.989M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 9.829M | 6.634M | 1.733M | 2.935M | 4.037M |
| Other Stockholder Equity | 627.665M | 489.692M | 463.796M | 454.741M | 373.657M |
| Property Plant Equipment | - | - | - | 1.567M | 6.332M |
| Total Current Assets | 209.819M | 132.751M | 153.881M | 194.791M | 147.105M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 178.263M | 83.239M | 128.233M | 151.663M | - |
| Net Receivables | - | - | - | 0.32M | - |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | 1.585M | 2.249M | 4.09M | 3.382M | 0.867M |
| Accumulated Other Comprehensive Income | 0.28M | 0.21M | 0.037M | -0.302M | - |
| Non Currrent Assets Other | 0.568M | 0.568M | 0.32M | 0.32M | 0.32M |
| Non Current Assets Total | 9.769M | 7.652M | 2.994M | 4.854M | 6.652M |
| Capital Lease Obligations | 9.829M | 6.634M | 1.733M | 2.935M | 4.037M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Investments | -93.281M | 46.772M | 26.965M | -151.164M | -1.77M |
| Total Cashflows From Investing Activities | -93.306M | 46.772M | 26.965M | -151.2M | -1.77M |
| Total Cash From Financing Activities | 129.609M | 17.338M | 2.935M | 75.757M | 118.611M |
| Net Income | -66.489M | -49.375M | -42.494M | -39.225M | -82.181M |
| Change In Cash | -12.84M | 19.255M | -10.718M | -109.568M | 97.175M |
| Begin Period Cash Flow | 44.051M | 24.228M | 34.946M | 144.514M | 47.339M |
| End Period Cash Flow | 31.211M | 43.483M | 24.228M | 34.946M | 144.514M |
| Total Cash From Operating Activities | -49.143M | -44.855M | -40.618M | -34.125M | -19.666M |
| Depreciation | -1.397M | 1.753M | 1.89M | 1.904M | 1.624M |
| Other Cashflows From Investing Activities | - | - | 0.027M | 0.176M | -0.202M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | - | - | -0M | 75.757M | 127.986M |
| Other Cashflows From Financing Activities | 129.609M | -0.775M | -0.159M | -0.48M | -0.281M |
| Capital Expenditures | 0.025M | 0.044M | 0.03M | 0.212M | 1.568M |
| Change In Working Capital | 9.179M | -4.142M | -2.908M | -1.263M | 6.245M |
| Other Non Cash Items | 10.375M | -1.651M | 5.966M | -0.871M | 0.041M |
| Free Cash Flow | -49.168M | -44.899M | -40.648M | -34.337M | -21.234M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 2 months ago | 4190854 |
| 2. | State Street® SPDR® S&P® Biotech ETF | 2 months ago | 3855953 |
| 3. | iShares Russell 2000 ETF | 2 months ago | 3137131 |
| 4. | Vanguard Institutional Extnd Mkt Idx Tr | 2 months ago | 1711952 |
| 5. | Fidelity Small Cap Index | 4 months ago | 1268479 |
| 6. | Russell 2000 Equity Index Fund B | 5 months ago | 822945 |
| 7. | Fidelity Extended Market Index | 3 months ago | 805577 |
| 8. | MEDICAL BioHealth EUR Acc | 3 months ago | 781382 |
| 9. | State St Russell Sm/Mid Cp® Indx SL Cl I | 2 months ago | 757600 |
| 10. | Vanguard Russell 2000 ETF | 2 months ago | 635116 |
| 11. | Royce Small-Cap Trust | 2 months ago | 576468 |
| 12. | iShares Russell 2000 Growth ETF | 2 months ago | 571013 |
| 13. | iShares Russell 2000 Value ETF | 2 months ago | 522428 |
| 14. | Royce Small-Cap Fund Invmt | 2 months ago | 490597 |
| 15. | State St Russell Sm Cap® Indx SL Cl I | 3 months ago | 425700 |
| 16. | Extended Equity Market Fund E | 5 months ago | 404207 |
| 17. | Extended Equity Market Fund B | 5 months ago | 404207 |
| 18. | Blackrock Extended Mkt Fund CF | 3 months ago | 402566 |
| 19. | HealthInvest Sustainable Healthcare E | 2 months ago | 395367 |
| 20. | JPMorgan Small Cap Value I | 3 months ago | 367304 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Orbimed Advisors, LLC | 5 months ago | 15219994 |
| 2. | Millennium Management LLC | 5 months ago | 3109286 |
| 3. | State Street Corp | 8 months ago | 3106513 |
| 4. | BRAIDWELL LP | 5 months ago | 2786778 |
| 5. | FMR Inc | 5 months ago | 2579711 |
| 6. | TANG CAPITAL MANAGEMENT LLC | 5 months ago | 16790809 |
| 7. | Suvretta Capital Management, LLC | 5 months ago | 14182379 |
| 8. | Blackstone Inc | 8 months ago | 9840108 |
| 9. | Vivo Capital, LLC | 5 months ago | 9545466 |
| 10. | Vanguard Group Inc | 5 months ago | 8048374 |
| 11. | Enavate Sciences GP, LLC | 5 months ago | 7788150 |
| 12. | Bvf Inc | 5 months ago | 7764842 |
| 13. | BlackRock Inc | 8 months ago | 7370747 |
| 14. | Adage Capital Partners Gp LLC | 5 months ago | 4436500 |
| 15. | JPMorgan Chase & Co | 8 months ago | 3998556 |
| 16. | Rock Springs Capital Management LP | 5 months ago | 3927202 |
| 17. | Deerfield Management Co | 5 months ago | 3606000 |
| 18. | Geode Capital Management, LLC | 5 months ago | 3502526 |
| 19. | Blue Owl Capital Holdings LP | 5 months ago | 3466525 |
| 20. | Sofinnova Ventures | 5 months ago | 3365446 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...